Article Details

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its ...

Retrieved on: 2021-05-11 09:56:15

Tags for this article:

Click the tags to see associated articles and topics

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its .... View article details on hiswai:

Excerpt

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up